ResMed Inc. filed an 8-K material event disclosure signaling a strategic review of its respiratory device and cloud-connected care platforms, placing $41 billion in market capitalization under scrutiny. The San Diego-based manufacturer controls 140 markets for sleep apnea and chronic obstructive pulmonary disease devices, with cloud infrastructure touching 1.5 million active patients across home care networks. The filing arrives as digital health infrastructure faces compression across telehealth and remote monitoring verticals, with connected-device margins under pressure from reimbursement headwinds and hospital capital equipment freezes.
The strategic review follows 18 months of margin compression in ResMed's Software-as-a-Service segment, which posted 11.2% operating margins in the most recent quarter versus 14.8% a year prior. Cloud-connected respiratory platforms now account for $980 million in annual recurring revenue, embedded in hospital discharge protocols and home health networks that face $2.3 billion in annual Medicare Advantage rate cuts effective January 2026. The review encompasses device manufacturing, software licensing, and cloud infrastructure — three verticals that separately command different multiples in the current market. ResMed's respiratory device business trades at 6.8x forward revenue while its SaaS contracts carry 4.2x multiples, a 38% valuation gap that strategic acquirers can arbitrage through structural separation.
Digital health consolidation has accelerated in the past 90 days, with private equity firms and strategic healthcare operators circling assets that carry both regulatory moats and embedded patient networks. ResMed's connected-care platform integrates with 470 hospital systems and feeds data into chronic disease management protocols worth $18 billion annually in the Medicare fee-for-service population. The company's device portfolio holds 340 active patents in non-invasive ventilation and adaptive pressure algorithms, intellectual property that commands premium multiples in medtech M&A. Strategic buyers include Philips, which exited the ventilator market under consent decree in 2023 and now seeks respiratory assets without legacy liability, and private equity infrastructure funds targeting recession-resistant healthcare cash flows with 80%+ gross retention rates.
Allocators should monitor ResMed's December earnings call for formal guidance on the review timeline, with separation or sale likely to surface in Q2 2025. The respiratory device segment generates $3.2 billion in annual revenue with 22% EBITDA margins, defensible in downturn scenarios due to clinical necessity and formulary lock-in. Cloud platform multiples will depend on demonstrated pricing power in the 2026 reimbursement cycle, where home health networks face rate compression but retain volume growth from aging demographics. Private equity interest will show in 13F filings due February 14, particularly from healthcare-focused infrastructure funds that acquired adjacent home medical equipment platforms in the past 24 months.
ResMed's installed base of 6.8 million active devices creates a natural acquirer advantage for operators with existing respiratory supply chains. The strategic review is not distress — it is revaluation arbitrage in a market that misprices bundled verticals.